地拉罗司要多少钱一盒呢？

Thalassemia is a rare genetic disease. In addition to iron removal and blood transfusion, most patients in China use oral dispersible tablets as treatment. Oral deferasirox treatment is far safer and more convenient than blood transfusion, and has fewer side effects. Today let’s take a look at how much does a box of deferasirox cost?

Deferasirox dispersible tablets can be used in patients with iron accumulation due to long-term blood transfusion (such as thalassemia or other rare anemias). It is suitable for children over two years old and adults. Corresponding to body weight, it is initially recommended to take deferasirox at a daily dose of 20 mg/kg, depending on the improvement of serum ferritin indicators. Usage and dosage are based on the patient's personal condition, constitution, family genetic history, and drug ingredients. The drug is accurately selected to truly prescribe the right medicine for the disease. At the same time, the medicine is accurately administered in the appropriate method, appropriate dose, and appropriate time.

According to Medical Companion Travel, Deferasirox is currently on the market in China, but it is not included in domestic medical insurance. If patients want to buy cheap Deferasirox, they can choose Deferasirox sold in India. Deferasirox produced by cipla, India, is 500mg*30 tablets/box, and the price is equivalent to RMB 500$. The original drug Deferasirox launched by Novartis in India is 400mg*30 tablets/box, priced at approximately RMB 700.

Deferasirox is currently the only oral iron chelator developed by Novartis. It was approved by the FDA in November 2005 for use in patients 2 years and older with chronic iron overload caused by blood transfusions. In December 2012, Deferasirox was approved by the European Commission for the treatment of chronic iron overload in patients aged 10 years and above with non-transfusion-dependent thalassemia (NTDT) syndrome who require chelation therapy due to contraindications or insufficiency of deferoxamine mesylate therapy. On January 23, 2013, the FDA approved a new indication for deferasirox for the treatment of chronic iron overload in patients aged 10 years and older with non-transfusion-dependent thalassemia (NTDT).

The above is the price content, I hope it can help you!